Shanghai Junshi Bioscience-h Stock price
Is Shanghai Junshi Bioscience-h a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.
Key metrics
Shanghai Junshi Bioscience-h Stock Analysis
Analyst Opinions
7 Analysts have issued a Shanghai Junshi Bioscience-h forecast:
Analyst Opinions
7 Analysts have issued a Shanghai Junshi Bioscience-h forecast:
Don't miss a Thing! We will send you all news about Shanghai Junshi Bioscience-h directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Shanghai Junshi Biosciences Co Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Shanghai, Shanghai and currently employs 2,903 full-time employees. The company went IPO on 2018-12-24. Shanghai Junshi Biosciences Co Ltd is a China-based company primarily engaged in the discovery, development and commercialisation of innovative drugs. The Company’s products primarily include TUOYI toripalimab, recombinant humanized anti-tumor anti-B-and T-lymphocyte attenuator (BTLA) monoclonal Tifcemalimab, MINDEWEI deuremidevir hydrobromide tablets, JUNMAIKANG adalimumab, JUNSHIDA ongericimab, programmed death-1 (PD-1) monoclonal antibody subcutaneous injection formulation and others. The products are primarily used to treat malignant tumors, autoimmune diseases, chronic metabolic diseases, neurologic diseases and infectious diseases. The firm primarily operates its businesses in the domestic and American markets.
| Head office | China |
| CEO | Ms. Zou |
| Employees | 2,903 |
| Website | www.junshipharma.com |


